Conjugated beta-1,3-linked glucans

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9439954
APP PUB NO 20110045015A1
SERIAL NO

12734795

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolyzed to a suitable form prior to conjugation.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • SMITHKLINE BEECHAM BIOLOGICALS S.A.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Berti, Francesco Colle Val d'Elsa, IT 50 157
Costantino, Paolo Colle Val d'Elsa, IT 53 308
Romano, Maria Rosaria Pontedera, IT 20 47

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 13, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 13, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00